Citalopram for Sx/Util in Acute Coronary Syndrome Patients

Status

Withdrawn

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01667744

Enrollment

Registered

2012-08-17

Start date

2016-01-01

Completion date

2021-02-16

Last updated

2022-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Angina, Acute Coronary Syndrome, Emotional Distress, Citalopram, Health Care Utilization

Brief summary

Symptoms (chest pain, shortness of breath, dizziness, etc.) and treatment usage (doctor or emergency room visits, testing, hospital days, etc.) in patients with Acute Coronary Syndromes are known to be related to emotional distress (Anxiety, Depression and Anger). In addition, behavioral treatment of emotional distress is known to decrease symptoms, and treatment usage. The present protocol tests whether the addition of a medication known to reduce emotional distress can also reduce symptoms and treatment usage. This will done by recruiting patients with ACS during their hospital stay, randomizing them to receive citalopram or placebo, and then examining their symptoms and treatment usage at 6 months.

Detailed description

Not applicable. Study not funded.

Interventions

DRUGCitalopram

10 mg/day

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Admission to hospital for chest pain/dyspnea, typical ECG changes plus positive tropinins

Exclusion criteria

* age less than 18 * cognitive impairment (per MMSE) * geographic unavailability for followup * unwillingness to participate * illiteracy * Hx cardiac transplant * untreated hypothyroidism * hepatic dysfunction * prior adverse reaction to citalopram * history of Bipolar Disorder * untreated Sleep Apnea * chronic steroid therapy * active substance abuse (e.g., within past year) * near term mortal illness * current mental health treatment * signitificant suicide risk

Design outcomes

Primary

Measure	Time frame	Description
Frequency of ACS Symptoms	6 months	Frequency of episiodes of chest pain, presyncope, dyspnea, fatigue and palpitations
Treatment usage	6 months	ER Visits, Hospital Days, Catheterizations, PTCAs/CABGs, Valve Surgery, AICD/Pacemaker, Treadmills, Echos, Nuclear Scans, Chest X-Rays

Secondary

Measure	Time frame	Description
Emotional Distress	6 months	Depression per PHQ9, Anxiety per GAD7 & Anxiety/Depression/AIAI per KSSFC

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026